J&J results beat estimates but Remicade concerns prevail

23 January 2018
jnjn_flickr_big

US healthcare giant Johnson & Johnson (NYSE: JNJ) slipped by 2.5% in the stock market in the two hours after it reported its fourth quarter and annual financial results for 2017.

This is despite J&J exceeding Wall Street estimates with its quarterly results overall, with the revenue total of $20.2 billion above the $20.1 billion expected, according to Thomson Reuters. Adjusted earnings per share (EPS) were $0.02 higher than anticipated, at $1.74, on adjusted net income of $4.78 billion, up about 10% from a year ago.

"The passage of legislation modernizing the US tax system enables J&J to invest in innovation at higher levels"

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical